$104.41
Value $181B
ABT and ZVRA stock compared: price, dividend, valuation and results, from SEC filings.
$104.41
Value $181B
$8.87
Value $521M
Abbott Laboratories (ABT) has a market value of $181B and Zevra Therapeutics (ZVRA) $521M. Over the last year, with dividends, ABT moved -15.2% and ZVRA -8.4%. The P/E is 38.6 for ABT and 6.8 for ZVRA. Dividend yield: ABT 2.41%, ZVRA none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$181B
ZVRA$521M
ABT is 348 times ZVRA
Revenue, 12 months
ABT$48.2B
ZVRA$148M
ABT is 326 times ZVRA
Net income, 12 months
ABT$4.7B
ZVRA$78M
ABT is 60 times ZVRA
Operating margin
ABT13.8%
ZVRA60.8%
47.0 points apart
ROIC
ABT6.3%
ZVRA36.3%
30.0 points apart
P/E
ABT38.6
ZVRA6.8
ABT is 5.7 times ZVRA
Dividend yield
ABT2.4%
ZVRA0.0%
2.4 points apart
5-year return
ABT-9.1%
ZVRA+5.6%
14.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-9.1%
ZVRA+5.6%
| Period | ABTWith dividends | ZVRAWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -15.2%Price -17.2% | -8.4%Price -8.4% |
| 3 years since November 20, 2023 | +9.9%+3.2% a yearPrice +3.2% | +98.0%+25.6% a yearPrice +98.0% |
| 5 years since November 19, 2021 | -9.1%-1.9% a yearPrice -17.7% | +5.6%+1.1% a yearPrice +5.6% |
| 10 years since November 21, 2016 | +216.8%+12.2% a yearPrice +162.6% | -86.5%-18.1% a yearPrice -86.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesZVRAZevra Therapeutics
| Price | $104.41 | $8.87 |
|---|---|---|
| Market value | $181B | $521M |
| Enterprise value (EV) | $208B | $325M |
| P/E | 38.6 | 6.8 |
| P/E, 5-year median | 33.7 | – |
| P/B | 3.6 | 2.2 |
| EV/EBIT | 31.3 | 3.6 |
| Free cash flow yield | 3.7% | 7.4% |
| Revenue, 12 months | $48.2B | $148M |
|---|---|---|
| Net income, 12 months | $4.7B | $78M |
| Free cash flow, 12 months | $6.8B | $38M |
| Earnings per share, 12 months | $2.69 | $1.19 |
| Revenue growth, year on year | 5.7% | 350.9% |
| Revenue growth a year, past | +5.1%over 5 years | +51.6%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | – |
| Gross margin | 56.9% | 95.4% |
|---|---|---|
| Operating margin | 13.8% | 60.8% |
| Net margin | 9.8% | 52.8% |
| ROIC | 6.3% | 36.3% |
| ROE | 9.1% | 41.1% |
| Cash | $4.3B | $196M |
|---|---|---|
| Total debt | $31.2B | $1.2M |
| Net debt / EBITDA | 3.3 | -2.1 |
| Interest cover | 6.7× | 24.6× |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $2.52 | – |
| Dividend growth a year, past | +10.4%over 5 years | – |
| Buyback yield | 0.5% | – |
| Shareholder yield | 2.9% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($181B) is about 348.4 times Zevra Therapeutics ($521M), at today's prices.
Since November 21, 2016, ABT's price moved +162.6% and ZVRA's -86.5%. With dividends: ABT +216.8% (+12.2% a year), ZVRA -86.5% (-18.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.41% for Abbott Laboratories and none for Zevra Therapeutics. Over the last twelve months they paid $2.52 and – per share.
At today's price, the P/E is 38.6 for ABT and 6.8 for ZVRA. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 52.8% for Zevra Therapeutics, and the operating margin 13.8% and 60.8%. Revenue was $48.2B and $148M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.